<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218855</url>
  </required_header>
  <id_info>
    <org_study_id>NMSG #12</org_study_id>
    <secondary_id>NFR 90000288</secondary_id>
    <nct_id>NCT00218855</nct_id>
  </id_info>
  <brief_title>Thalidomide to Patients With Previously Untreated Multiple Myeloma</brief_title>
  <official_title>A Phase 3 Study With Randomization to Melphalan/Prednisone/Thalidomide Versus Melphalan/Prednisone/Placebo to Patients With Previously Untreated Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Myeloma Study Group, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effect of thalidomide in patients with multiple
      myeloma. The patients receive either thalidomide or a placebo tablet (neither patient nor
      doctor know which of these are given) in addition to the ordinary chemotherapeutic drug
      against multiple myeloma. We will find out for how long time the patients will stay free of
      the disease and for how long time they will live, and can evaluate whether thalidomide is a
      beneficial drug against this disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thalidomide has recently emerged as an effective treatment for patients with myeloma
      refractory to conventional chemotherapy. So far only limited experience is available on
      thalidomide for newly diagnosed myeloma. Therefore the Nordic Myeloma Study Group decided to
      perform a trial comparing traditional melphalan-prednisone therapy with melphalan-prednisone
      + thalidomide/placebo. The study design is a multicentre double-blind randomised
      placebo-controlled trial. Mainly patients &gt;65 years of age will be included since patients
      &lt;65 years will be treated with high dose chemotherapy with autologous stem cell support. The
      primary end-point is overall survival. Secondary end-points are quality of life, response
      rate, time to response, response duration and toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>october 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of response</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 2. response</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of 2. response</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 2. progression</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to definitive treatment failure</measure>
    <time_frame>october 2007</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>thalidomide, Talix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with multiple myeloma in need of treatment

        Exclusion Criteria:

          -  Previous treatment against multiple myeloma

          -  Need of high dose chemotherapy with autologous stem cell support

          -  Women in fertile age

          -  Psychiatric disease or mental reduction leading to lack of cooperation

          -  Lack of consent

          -  Life expectancy below 3 months

          -  Active cancer of other etiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Waage, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Haematology, St. Olavs hospital/NTNU, N-7006 Trondheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Haematology, St. Olavs hospital/NTNU</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6.</citation>
    <PMID>20448107</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Phase 3, randomised, double blind study</keyword>
  <keyword>thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

